Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Calvez

Showing results (201-210 of 329) with videos related to

Pageof 33
Sort By:
The Journal of Antimicrobial Chemotherapy|May 27, 2014
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytesMichela Pollicita, Matteo Surdo, Fabiola Di Santo, et al.
Plos One|January 26, 2013
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypesCharlotte Charpentier, Sidonie Lambert-Niclot, Claudia Alteri, et al.
Life (Basel, Switzerland)|December 23, 2022
SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization TestStephane Marot, Djeneba Bocar Fofana, Philippe Flandre, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2008
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitroIsabelle Malet, Olivier Delelis, Marc-Antoine Valantin, et al.
Haematologica|September 21, 2004
High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV diseaseJean Gabarre, Anne-Geneviève Marcelin, Nabih Azar, et al.
Plos One|December 1, 2016
TLR-2 Recognizes Propionibacterium acnes CAMP Factor 1 from Highly Inflammatory StrainsCoralie Lheure, Philippe Alain Grange, Guillaume Ollagnier, et al.
The Journal of Antimicrobial Chemotherapy|April 9, 2014
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitorsIsabelle Malet, Laura Gimferrer Arriaga, Anna Artese, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2012
Risk factors for raltegravir resistance development in clinical practiceIsabelle Malet, Slim Fourati, Laurence Morand-Joubert, et al.
British Journal of Haematology|February 20, 2025
Longitudinal analysis of lentiviral and retroviral chimeric antigen receptors' integration sites reveals distinct clonal evolutionary patternsVincent Guiraud, Jerome Alexandre Denis, Ghizlane Benhafoun, et al.
Plos One|October 8, 2013
A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityDavid W Wright, Ilona P Deuzing, Philippe Flandre, et al.
Pageof 33

Showing results (201-210 of 329) with videos related to

Sort By:
Pageof 33
The Journal of Antimicrobial Chemotherapy|May 27, 2014
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytesMichela Pollicita, Matteo Surdo, Fabiola Di Santo, et al.
Plos One|January 26, 2013
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypesCharlotte Charpentier, Sidonie Lambert-Niclot, Claudia Alteri, et al.
Life (Basel, Switzerland)|December 23, 2022
SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization TestStephane Marot, Djeneba Bocar Fofana, Philippe Flandre, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2008
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitroIsabelle Malet, Olivier Delelis, Marc-Antoine Valantin, et al.
Haematologica|September 21, 2004
High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV diseaseJean Gabarre, Anne-Geneviève Marcelin, Nabih Azar, et al.
Plos One|December 1, 2016
TLR-2 Recognizes Propionibacterium acnes CAMP Factor 1 from Highly Inflammatory StrainsCoralie Lheure, Philippe Alain Grange, Guillaume Ollagnier, et al.
The Journal of Antimicrobial Chemotherapy|April 9, 2014
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitorsIsabelle Malet, Laura Gimferrer Arriaga, Anna Artese, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2012
Risk factors for raltegravir resistance development in clinical practiceIsabelle Malet, Slim Fourati, Laurence Morand-Joubert, et al.
British Journal of Haematology|February 20, 2025
Longitudinal analysis of lentiviral and retroviral chimeric antigen receptors' integration sites reveals distinct clonal evolutionary patternsVincent Guiraud, Jerome Alexandre Denis, Ghizlane Benhafoun, et al.
Plos One|October 8, 2013
A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityDavid W Wright, Ilona P Deuzing, Philippe Flandre, et al.
Pageof 33